Biochemical and Neuroimaging Studies in Subjective Cognitive Decline: Progress and Perspectives
Open accessAbstract
Summary: Neurodegeneration due to Alzheimer's disease (AD) can progress over decades before dementia becomes apparent. Indeed, patients with mild cognitive impairment (MCI) already demonstrate significant lesion loads. In most cases, MCI is preceded by subjective cognitive decline (SCD), which is applied to individuals who have self‐reported memory‐related complaints and has been associated with a higher risk of future cognitive decline and conversion to dementia. Based on the schema of a well‐received model of biomarker dynamics in AD pathogenesis, it has been postulated that SCD symptoms may result from compensatory changes in response to β‐amyloid accumulation and neurodegeneration. Although SCD is considered a prodromal stage of MCI, it is also a common manifestation in old age, independent of AD, and the predictive value of SCD for AD pathology remains controversial. Here, we provide a review focused on the contributions of cross‐sectional and longitudinal analogical studies of biomarkers and neuroimaging evidence in disentangling under what conditions SCD may be attributable to AD pathology. In conclusion, there is promising evidence indicating that clinicians should be able to differentiate pre‐AD SCD based on the presence of pathophysiological biomarkers in cerebrospinal fluid (CSF) and neuroimaging. However, this neuroimaging approach is still at an immature stage without an established rubric of standards. A substantial amount of work remains in terms of replicating recent findings and validating the clinical utility of identifying SCD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Symptoms of SCD are associated with specific and distinctive underlying pathological events, such as abnormal deposition of ß-amyloid and tau proteins, gray matter atrophy, disruptions in WM and deficits in brain function.
“An increasing number of neuroimaging studies have indicated that the symptoms of SCD are associated with specific and distinctive underlying pathological events, such as the abnormal deposition of ß-amyloid and tau proteins, gray matter atrophy, disruptions in the white matter (WM) and deficits in brain function [3, 10, 11].”
From Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease (2020) · cites this paper as [10]
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589 · see citing works
Mild Cognitive Impairment: Ten Years Later
Petersen, R. C., Roberts, R. O., Knopman, D. S., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Smith, G. E., & Jack, C. R. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.266 · Cited by 1,447 · see citing works
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort
Risacher, S., Saykin, A., Wes, J., Shen, L., Firpi, H., & McDonald, B. (2009) · Current Alzheimer Research · doi:10.2174/156720509788929273 · Cited by 538 · see citing works
Relationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373 · see citing works
The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease.
Reisberg, B., Prichep, L., Mosconi, L., John, E. R., Glodzik‐Sobanska, L., Boksay, I., Monteiro, I., Torossian, C., Vedvyas, A., Ashraf, N., et al. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.11.017 · Cited by 312 · see citing works
Perrotin, A. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.666 · Cited by 300 · see citing works
van Harten, A. C., Visser, P. J., Pijnenburg, Y. A. L., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.08.004 · Cited by 197 · see citing works
Gray matter atrophy pattern in elderly with subjective memory impairment
Peter, J., Scheef, L., Abdulkadir, A., Boecker, H., Heneka, M., Wagner, M., Koppara, A., Klöppel, S., Jessen, F., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1764 · Cited by 165 · see citing works
Evidence of Neuronal Compensation During Episodic Memory in Subjective Memory Impairment
Erk, S. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.80 · Cited by 147 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00395-3 · Cited by 265 · see citing works
Self-citationCheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150 · see citing works
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Ray, B., Maloney, B., Sambamurti, K., Karnati, H. K., Nelson, P. T., Greig, N. H., & Lahiri, D. K. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0709-x · Cited by 91 · see citing works
Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project
Initiative, F. T. A. D. N., van Maurik, I. S., Slot, R. E. R., Verfaillie, S. C. J., Zwan, M. D., Bouwman, F. H., Prins, N. D., Teunissen, C. E., Scheltens, P., Barkhof, F., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0487-y · Cited by 47 · see citing works
Diminution of context association memory structure in subjects with subjective cognitive decline
Fan, L., Lai, Y., Chen, T., Hsu, Y., Chen, P., Huang, K., Cheng, T., Tseng, W. I., Hua, M., Chen, Y., et al. (2018) · Human Brain Mapping · doi:10.1002/hbm.24022 · Cited by 40 · see citing works
- Authors
- Sun, Y., Yang, F., Lin, C., & Han, Y.
- Affiliations
- Capital Medical University (CN)
- Tri-Service General Hospital (TW)
- National Yang Ming University (TW)
- Corresponding author
- Lin, Ching‐Po
- Han, Ying
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2015-04-13
- Volume
- 21
- Issue
- 10
- Pages
- 768-775
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- PMC
- PMC6493085
- OpenAlex
- W2102528134
- Cited by
- 71
- References
- 9
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 8 · 2023: 11 · 2022: 4 · 2021: 4 · 2020: 8 · 2019: 10 · 2018: 4 · 2017: 5 · 2016: 2 · 2015: 4
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- CNS Neuroscience & Therapeutics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (#30970823, 31371007, 81430037)
- Beijing Municipal Science & Technology Commission (#Z131100006813022)
- Chinese Health and Family Planning Committee
- Taiwan National Science Council (NSC 102-2321-B-010-023)
- National Health Research Institute (NHRI-EX103-10310EI)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
- Keywords
- subjective cognitive decline, Alzheimer's disease, mild cognitive impairment, prodromal Alzheimer's disease, biomarkers, cerebrospinal fluid biomarkers, neuroimaging, amyloid-beta, neurodegeneration, memory impairment, conversion to dementia, compensatory brain changes
- MeSH terms
- Brain, Cognition Disorders, Humans, Perception, Biomarkers, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
